| Name | Title | Contact Details |
|---|
Islet Sciences is a clinical stage biotechnology company engaged in the research, development, and commercialization of new medicines and technologies for the treatment and diagnosis of metabolic disease and related indications where there is significant measurable unmet medical need. The rising incidence of obesity is associated with many obesity-related health complications, including cardiovascular disease, diabetes, hyperlipidemia, hypertension, nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH). This constellation is also recognized as the metabolic syndrome and is characterized by underlying insulin resistance. These various diseases have interrelated risk factors and markers, such that often treatment of one disease may allow new therapies and opportunities for treatment in one of these related indications. Our focused effort to develop new therapies and related diagnostics for metabolic related diseases establishes us as a recognized leader in a large and growing market.
Delaware BioScience Association has a broad-based membership including pharmaceutical, biotechnology, medical devices, analytical equipment and agricultural products; as well as representatives from academia, medical research, workforce training and other supporting organizations (financial, legal, marketing, consulting, engineering and construction, etc.) that serve the bioscience community. Delaware Bio is focused on being a unified voice for Delaware and the region`s bioscience community to accelerate the growth of human, animal, plant, and industrial biosciences.
Folio Conversant is the premier provider of research services and biospecimen solutions. We offer an extensive array of quality biospecimens, particularly Human tissue and biofluids, supported by comprehensive laboratory and analytical services. Science does not stand still. Our goal is to become a key partner in supporting your team`s research and development in order to accelerate new diagnostic and therapeutic options for patients.
Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology. Exoneural biology is broadly implicated in human health and disease. Fueled by our dynamic Exoneural Medicine Platform™, we are creating new medicines across multiple therapeutic areas, starting with cancer and inflammatory diseases.
Portage is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns.